Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study
Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: eine retrospektive Kohortenstudie
Frontiers in Psychiatry · 09.07.2026 · 17
DOI: 10.3389/fpsyt.2026.1867963 ↗Auf einen Blick
Bei Erwachsenen mit therapieresistenter Depression waren intranasales Esketamin und intravenöses Ketamin in einer Gemeinschaftspraxis mit starken PHQ-9-Verbesserungen verbunden. Zwischen den Gruppen zeigten sich keine statistisch signifikanten Unterschiede.
Fragestellung
Wie unterscheiden sich intranasales Esketamin und intravenöses Ketamin bei der Einleitungsbehandlung einer therapieresistenten Depression im Praxisalltag?
Methode
Einzentrische retrospektive Kohortenstudie bei Erwachsenen von 18 bis 65 Jahren in einer psychiatrischen Gemeinschaftspraxis vom 1. Januar bis 31. Dezember 2025.
Ergebnisse
63 Patient:innen (Esketamin n=37; i.v. Ketamin n=26). PHQ-9-Änderung: -10,31±5,59 vs. -9,50±5,69; mittlere Differenz 0,81 (95 %-KI -2,12 bis 3,75).
Einschränkungen
Kleine Stichprobe; unterschiedliche Protokolle zwischen den Gruppen; begrenzte Power für Gruppenvergleiche.
Schlussfolgerung der Autor:innen
Die Einleitungsbehandlung mit intranasalem Esketamin und intravenösem Ketamin war in der ambulanten Versorgung mit robusten antidepressiven Effekten verbunden. Fehlende Gruppenunterschiede sollten nicht als Gleichwertigkeit interpretiert werden.
Kernaussagen
- PHQ-9 sank in beiden Gruppen deutlich.
- Keine statistisch signifikanten Gruppenunterschiede.
- Keine schweren unerwünschten Ereignisse berichtet.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Psychiatry, online erschienen am 09.07.2026. Verfasst von Patrice A Bellanti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ketamine Health and Wellness Clinics of Ohio, Dublin, OH, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Introduction
Intravenous (IV) ketamine and intranasal esketamine are NMDA receptor antagonists used for treatment-resistant depression (TRD). Both have demonstrated efficacy in controlled trials, but observational evidence from real-world community settings is limited.
Methods
We conducted a single-center retrospective cohort study of adults aged 18 to 65 receiving induction therapy for TRD with intranasal esketamine or IV ketamine at a community psychiatric clinic from January 1 through December 31, 2025. Patients with prior exposure to either medication or to oral ketamine derivatives were excluded. The primary outcome was change in Patient Health Questionnaire-9 (PHQ-9) score from baseline to end of induction. Secondary outcomes included response (≥50% PHQ-9 reduction), remission (final PHQ-9 ≤4), clinically meaningful improvement (≥5 PHQ-9 reduction), induction completion, and adverse events. Within-group and per-protocol analyses were exploratory.
Results
Sixty-three patients met inclusion criteria (esketamine n=37; IV ketamine n=26). Baseline PHQ-9 scores were similar (18.22±4.49 vs. 18.27±5.41; P = 0.967), as was mean change from baseline (-10.31±5.59 vs. -9.50±5.69; mean difference 0.81, 95% CI -2.12 to 3.75; P = 0.589). Response rates were 64.9% vs. 69.2% (RR 0.94, 95% CI 0.66 to 1.33; P = 0.790), remission 32.4% vs. 23.1% (RR 1.41, 95% CI 0.61 to 3.26; P = 0.573), and clinically meaningful improvement 83.8% vs 73.1% (RR 1.15, 95% CI 0.87 to 1.51; P = 0.353). Induction completion exceeded 90% in both groups; one patient per cohort discontinued from intolerable side effects, and no serious adverse events occurred. Within-group PHQ-9 reduction was large: 10.31±5.59 points (paired t[34]=10.91; P<0.001; Cohen’s d=1.84) for esketamine and 9.50±5.69 points (paired t[23]=8.18; P<0.001; Cohen’s d=1.67) for ketamine. Findings remained statistically significant and clinically large under a pre-specified baseline observation carried forward (BOCF) sensitivity analysis (Cohen’s d=1.65 and 1.45).
Conclusions
Induction therapy with intranasal esketamine and intravenous ketamine was associated with robust antidepressant effects in a community outpatient setting, consistent with prior trial data. The modest sample size limits power to detect between-group differences and increases the risk of type II error; the absence of statistically significant between-group differences should therefore not be interpreted as evidence of equivalence. Protocol asymmetry between arms (esketamine: 12 sessions over 8 weeks; IV ketamine: 6 sessions over 3 weeks) further limits direct comparison of endpoint values between groups. Practical considerations including insurance coverage, cost, and administration logistics may help guide treatment selection. Longitudinal follow-up is planned to characterize treatment durability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ketamine Health and Wellness Clinics of Ohio, Dublin, OH, United States.
Zitieren
APA
Bellanti, P. A., Lewis, J., Seifferth, B., & Adams, D. Z. (2026). Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1867963
Vancouver
Bellanti PA, Lewis J, Seifferth B, Adams DZ. Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1867963
BibTeX
@article{Bellanti2026,
author = {Bellanti, Patrice A and Lewis, Jordan and Seifferth, Brian and Adams, Daniel Z},
title = {Real-world outcomes of intranasal esketamine and intravenous ketamine induction therapy for treatment-resistant depression in a community clinic: a retrospective cohort study},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1867963}
}
EUVIMED